The total human evidence base, as of this writing, consists of the following: 1) a Phase I safety trial of 42 healthy volunteers that was registered in 2015, canceled in 2016, and never published, 2) a retrospective case series of 12 patients with knee pain, no control group, and no validated outcome measure, and 3) a 2025 pilot safety study involving two healthy adults who received intravenous infusions at a single private clinic in Florida
The utilization of the nanohybrid system aimed to specifically target folate receptor-overexpressing HeLa cells, facilitating the efficient delivery of doxorubicin to cancer cells
Glutathione and kojic acid
Abstract Purpose Bispecific antibody-drug conjugates (BsADCs) represent a promising strategy to overcome limitations of conventional ADCs in breast cancer, such as tumor heterogeneity and inefficient internalization
The findings underscore glutathione's protective function in brain health and indicate that stress-related pathways affecting antioxidant systems may represent new avenues for medication development in treating depression